3 Active Ingredients and Custom Manufacturing Specialist, Paracetamol and Formulations Leader and Crop Science Innovator Stocks With a Strong Future Roadmap: Neuland Laboratories, Granules India and PI Industries

API, formulations and crop science stocks let investors follow companies that serve a growing part of the Indian economy. Neuland Laboratories, Granules India and PI Industries cover an active ingredients and custom manufacturing specialist, a paracetamol and formulations leader and a crop science innovator.

This list covers three API, formulations and crop science stocks with complete current figures: Neuland Laboratories, Granules India and PI Industries. Every figure comes from the latest reported financials and the 28 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are API, Formulations and Crop Science Stocks?

API, formulations and crop science stocks are listed companies that make active pharmaceutical ingredients and supply innovator companies through custom manufacturing, produce intermediates and finished dosage forms and sell crop protection products while making complex molecules for global innovators. Their earnings depend on export orders, approvals and product mix.

API, Formulations and Crop Science Stocks at a Glance

On valuation, Granules India trades at a P/E below the industry P/E, while Neuland Laboratories and PI Industries trade above it, which reflects the growth the market already expects. Readers comparing API, formulations and crop science stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do API, Formulations and Crop Science Stocks Have a Strong Roadmap in India?

API, formulations and crop science stocks have a strong roadmap in India because global firms keep outsourcing complex manufacturing to India and demand for generics and crop protection stays steady across markets.

• Outsourcing trend. Global firms add Indian partners.
• Scale benefits. Large plants support volume leadership.
• Innovator ties. Custom work builds long term relationships.

Why Neuland Laboratories Features Among These API, Formulations and Crop Science Stocks

Among the API, formulations and crop science stocks on this list, Neuland Laboratories, based in Hyderabad, makes active pharmaceutical ingredients for generic drugs and runs a custom manufacturing business that supplies innovator companies.

Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%.

The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0.

Roadmap: The company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.

What to watch: Custom manufacturing revenue can move between quarters, so review the full-year trend.

Why Granules India Features Among These API, Formulations and Crop Science Stocks

Among the contract manufacturing shares on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.

The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0.

Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore.

Roadmap: The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.

What to watch: Monitor new product approvals and the share of finished dosages in total sales.

Why PI Industries Features Among These API, Formulations and Crop Science Stocks

Among the three companies on this list, PI Industries is a Udaipur-based agrochemical and custom synthesis company. It sells crop protection products in India and manufactures complex molecules for global innovators, and it has added pharma and specialty chemistry capabilities.

Revenue rose from Rs 5,401 crore in FY22 to Rs 7,024 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 844 crore in FY22 to Rs 1,321 crore in FY26, which works out to a compound annual growth rate of 11.9%.

The company has a return on equity of 11.8%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 33,166 crore. The stock trades at a P/E of 28.5, above the industry P/E of 23.3.

Roadmap: The company is building long-term supply contracts for global customers, launching new crop protection brands and widening into pharma and other specialty areas. Strong research and plant capacity support its pipeline.

What to watch: Check the growth of custom synthesis orders and new product launches.

Neuland Laboratories vs Granules India vs PI Industries on Key Financials

The table below sets the three API, formulations and crop science stocks side by side on revenue, profit and margin, using reported figures.

Neuland Laboratories posts the highest return on equity in this group at 19.4%. PI Industries has the largest FY26 revenue at Rs 7,024 crore, and Neuland Laboratories shows the fastest revenue growth with a 21.1% compound annual rate. A useful habit with API, formulations and crop science stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in API, Formulations and Crop Science Stocks

Every theme carries risks that deserve a check before any decision. For these API, formulations and crop science stocks, the main points are:

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Currency moves. Export earnings move with the rupee.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter API, formulations and crop science stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on API, Formulations and Crop Science Stocks

API, formulations and crop science stocks reward investors who follow demand trends, order books and margins together. Neuland Laboratories, Granules India and PI Industries each have a clear plan to grow. Based on the 28 October 2026 close, Neuland Laboratories trades at Rs 19,970, Granules India at Rs 840.45 and PI Industries at Rs 2,055.

Download the Univest iOS App or Univest Android App to track API, formulations and crop science stocks, set price alerts and get research-backed stock ideas.

What are API, formulations and crop science stocks?

Ans. API, formulations and crop science stocks are listed companies that make active pharmaceutical ingredients and supply innovator companies through custom manufacturing, produce intermediates and finished dosage forms and sell crop protection products while making complex molecules for global innovators. Their earnings depend on export orders, approvals and product mix. This list looks at three of them, Neuland Laboratories, Granules India and PI Industries, using reported FY22 to FY26 financials and the 28 October 2026 closing prices.

Which API, formulations and crop science stocks are covered in this list?

Ans. This list covers Neuland Laboratories, Granules India and PI Industries. Based on the 28 October 2026 close, Neuland Laboratories traded at Rs 19,970, Granules India at Rs 840.45 and PI Industries at Rs 2,055. Their return on equity ranges from 11.7% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 21.1%.

Why do API, formulations and crop science stocks have a strong future roadmap in India?

Ans. API, formulations and crop science stocks have a strong roadmap in India because global firms keep outsourcing complex manufacturing to India and demand for generics and crop protection stays steady across markets. The main drivers are as follows. Outsourcing trend. Global firms add Indian partners. Scale benefits. Large plants support volume leadership. Innovator ties. Custom work builds long term relationships. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Neuland Laboratories performed financially?

Ans. Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.

How has Granules India performed financially?

Ans. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.

How has PI Industries performed financially?

Ans. Revenue rose from Rs 5,401 crore in FY22 to Rs 7,024 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 844 crore in FY22 to Rs 1,321 crore in FY26, which works out to a compound annual growth rate of 11.9%. The company has a return on equity of 11.8%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 33,166 crore. The stock trades at a P/E of 28.5, above the industry P/E of 23.3. Looking ahead, the company is building long-term supply contracts for global customers, launching new crop protection brands and widening into pharma and other specialty areas. Strong research and plant capacity support its pipeline.

What risks should investors check before buying API, formulations and crop science stocks?

Ans. Investors should check a few risks before buying API, formulations and crop science stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of API, formulations and crop science stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 28 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.